Genzyme, a Sanofi company, on Friday announced that the Food and Drug Administration approved Lemtrada (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis.
The Food and Drug Administration has declined to approve a drug made by Genzyme Corp. for certain forms of multiple sclerosis, the company said Monday.
The Food and Drug Administration has approved a new drug for multiple sclerosis.
Genzyme has named leaders of two units that are part of the core focus of the drug maker's business.
Sanofi has appointed David Meeker as CEO of Genzyme, the French drug maker said.